Second-line / Previously Treated Metastatic Pancreatic Cancer (mPDAC)

Authored by Open Medicine, published on 2026-07-09 16:21:55.0

The algorithm is broadly aligned with current practice for previously treated metastatic PDAC in emphasizing performance status assessment, clinical trial enrollment, molecular profiling, and use of evidence-based cytotoxic options (notably nal-IRI + 5-FU/LV after gemcitabine-based therapy). The standard-therapy branches are consistent with major guidelines, though optimal sequencing between gemcitabine/nab-paclitaxel and 5-FU–based regimens after first line is individualized and supported mainly by guideline consensus and non-randomized comparative data. The daraxonrasib (RASolute-302) pathway is explicitly noted as pending peer-reviewed publication, and should be considered investigational until full data and guideline incorporation.

Patient with metastatic pancreatic adenocarcinoma previously treated with one prior line of therapy (5-fluorouracil (5-FU) based or gemcitabine-based regimen)

Radiographically confirmed metastatic disease ECOG PS 0–2; disease progression on ≥1 prior systemic therapy for metastatic disease Adequate organ function (Clinical trial participation always encouraged)
- Assess performance status, prior therapy, organ function, goals of care
  
  PS and organ function are core determinants of whether multi-agent chemotherapy is appropriate versus single-agent therapy or best supportive care, and goals-of-care discussions are recommended throughout metastatic PDAC management.
  - Comprehensive molecular profiling (NGS ± ctDNA if tissue limited)
    
    Test for KRAS, NRAS, HRAS mutation status Ideally performed at initial diagnosis for all patients; repeat ctDNA/NGS if prior results unavailable or insufficient. See testing algorithm: Molecular Testing for Pancreatic Cancer.
    - Targetable RAS alteration
      
      The RASolute-302 population included tumors with RAS G12, G13, or Q61 mutations, plus patients with no RAS mutation identified. The trial enrolled: RAS G12 mutations (majority) RAS G13 mutations RAS Q61 mutations Small number with no RAS mutation identified
      - Consider daraxonrasib + best supportive care (BSC)
        
        Daraxonrasib + Best Supportive Care (BSC): Daraxonrasib 300 mg orally once daily (continuous). Continue until disease progression, unacceptable toxicity, or patient withdrawal. Monitor: CBC, CMP, Mg, Phos; assess AEs and adherence.
        
        At progression (consider trial, alternate systemic therapy, BSC)
        
        Consider clinical trial Standard cytotoxic chemotherapy options (e.g., nal-IRI + 5-FU/LV, gemcitabine + nab-paclitaxel, FOLFIRINOX if appropriate); Best supportive care
    - RAS wild-type / no actionable RAS alteration identified
      - Standard systemic therapy based on prior regimen exposure; consider clinical trial; best supportive care (BSC)
        
        Nal-IRI + 5-FU/LV Gemcitabine + nab-paclitaxel FOLFIRINOX (if PS 0–1 and appropriate) Consider clinical trial Best supportive care Wild-type KRAS tumors are not candidates for daraxonrasib.
        
        At progression (consider trial, alternate standard regimen, BSC)
        
        Consider clinical trial Alternate standard regimen not previously received Best supportive care
NOTE

Early palliative/supportive care integration is recommended throughout treatment. Algorithm informed by phase III RASolute-302 results published in NEJM (2026). Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.
Jump to first-line algorithm: Initial Treatment for Metastatic Pancreatic Cancer

tos privacy Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer